Wczytywanie spółki
Just reported
Q3 2026 results
From Moderna's results release of 6 listopada 2026; its quarterly report has since been filed.
Revenue
Actual
1,31B USD
+29% y/y
Guided
—
No guide given
EPS, GAAP
Actual
0,38 USD
Guided
—
No guide given
Operating income, GAAP
Actual
130M USD
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Moderna is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B USDA+
EXELExelixis, Inc.16,8B USDA+
JAZZJazz Pharmaceuticals plc15,5B USDA
TECHBIO-Techne Corp11,4B USDA+
HALOHalozyme Therapeutics, Inc.11,4B USDA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 paź 2026CBGraded C, now B
MCKMckesson Corporation4 lis 2026BAGraded B, now A
CVSCVS Health Corp4 lis 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 lis 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 paź 2026CAGraded C, now A
Jak zarabia
- COVID-19 vaccine sales, including Spikevax and mNEXSPIKE93%
- Payments for manufacturing capacity4%
- Government and other grants1%
- Collaboration revenue1%
- Licensing and royalties1%
- RSV vaccine sales, including mRESVIA0%
Udziały w przychodach to szacunki za year ended 2025-12-31, a nie dane z raportu złożonego do regulatora.
Konkuruje z
Co sprzedaje6
Spikevax
A COVID-19 vaccine updated to target circulating virus variants.
mNEXSPIKE
A COVID-19 vaccine that uses a lower mRNA dose than Spikevax and focuses the immune response on key parts of the virus.
mRESVIA
An RSV vaccine for older adults and certain adults at increased risk of severe RSV illness.
Pokaż 3 więcej
mFLUSIVA
An influenza vaccine approved in the United States and Canada for adults aged 50 and older; commercial sales began in September 2026.
mCOMBRIAX
A vaccine combining protection against influenza and COVID-19, authorized in Europe and Canada for adults aged 50 and older; it had not been commercialized by September 30, 2026.
Intismeran autogene (mRNA-4157)
An investigational personalized cancer treatment designed around mutations in an individual patient's tumor; it is being developed with Merck alongside pembrolizumab.
Kto to kupuje4
- Wholesalers and distributors, which are the main route for sales in the United States.
- Retail pharmacies, health care providers and government entities, which also buy vaccines in the United States.
- Governments and international organizations that purchase vaccines.
- Governments in the United Kingdom, Canada and Australia, which have multi-year commitments to purchase mRNA products.
Na czym się opiera i co może to zburzyć
Od czego zależy ta działalność
- 1COVID-19 vaccine sales made up 93.1% of revenue in 2025, tying revenue closely to demand for those vaccines.
- 2Vaccine sales are seasonal and depend on public health recommendations, changes in circulating viruses and whether people choose to get vaccinated.
- 3Some materials and manufacturing processes rely on single-source suppliers, and the company also uses outside manufacturers and suppliers.
- 4Intismeran autogene is being developed with Merck, with development costs and potential profits or losses generally shared equally.
- 5Vaccine products can require cold storage and careful shipping.
Co może pójść nie tak
- 1Demand for seasonal vaccines can change with public health recommendations, virus circulation, customer orders and willingness to vaccinate; these changes can affect sales.
- 2Clinical trials and regulatory reviews may delay or prevent approval of new vaccines and treatments; the influenza vaccine mRNA-1010 had faced a regulatory filing setback before its amended application was accepted for review.
- 3Manufacturing or supply problems, including supplier interruptions, product-release issues or failures to maintain required shipping and storage conditions, could delay or limit product supply.
Pełne sprawozdania finansowe →
O spółce Moderna, Inc.
Moderna makes vaccines using messenger RNA (mRNA), which gives cells instructions to make a protein that can help prevent or treat disease. It also develops mRNA-based treatments, including a personalized cancer treatment being developed with Merck and treatments for rare inherited diseases. As of September 30, 2026, it had five approved products, though its flu-plus-COVID vaccine had not yet been commercialized.
- Siedziba
- Cambridge, Massachusetts
- Rok założenia
- 2010
- Notowana na
- Nasdaq
- Koniec roku obrotowego
- December 31
Zbudowane z własnych raportów spółki Moderna, Inc. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.